Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study

Luca Filippi*, Giacomo Cavallaro, Elettra Berti, Letizia Padrini, Gabriella Araimo, Giulia Regiroli, Genny Raffaeli, Valentina Bozzetti, Paolo Tagliabue, Barbara Tomasini, Annalisa Mori, Giuseppe Buonocore, Massimo Agosti, Angela Bossi, Gaetano Chirico, Salvatore Averse, Pina Fortunato, Silvia Osnaghi, Barbara Cavallotti, Martina SuzaniMaurizio Vanni, Giulia Borsari, Simone Donati, Giuseppe Nascimbeni, Daniel Nardo, Stefano Piermarocchi, Giancarlo la Marca, Giulia Forni, Silvano Milani, Ivan Cortinovis, Maura Calvani, Paola Bagnoli, Massimo Dal Monte, Anna Maria Calvani, Alessandra Pugi, Eduardo Villamor, Gianpaolo Donzelli, Fabio Mosca

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number180
Pages (from-to)1-12
Number of pages12
JournalFrontiers in pediatrics
Volume7
DOIs
Publication statusPublished - 7 May 2019

Keywords

  • propranolol
  • beta blocker
  • proliferative retinopathy
  • angiogenesis
  • preterm newborn
  • OXYGEN-INDUCED RETINOPATHY
  • ENDOTHELIAL GROWTH-FACTOR
  • NITRIC-OXIDE
  • ORAL PROPRANOLOL
  • MOUSE MODEL
  • PREVENTION
  • HYPOXIA
  • PILOT

Cite this

Filippi, L., Cavallaro, G., Berti, E., Padrini, L., Araimo, G., Regiroli, G., Raffaeli, G., Bozzetti, V., Tagliabue, P., Tomasini, B., Mori, A., Buonocore, G., Agosti, M., Bossi, A., Chirico, G., Averse, S., Fortunato, P., Osnaghi, S., Cavallotti, B., ... Mosca, F. (2019). Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study. Frontiers in pediatrics, 7, 1-12. [180]. https://doi.org/10.3389/fped.2019.00180